Hendrik Peter Scholl insider trades: Belite Bio (BLTE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Hendrik reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | BLTE | ↓ Sell | 500 | $165.32 | $83K | By Bioptima Ltd. | Oct 5, 2026 (4d) |
| Jun 18, 2026 | BLTE | ↓ Sell | 10,000 | $145.24 | $1.5M | By Bioptima Ltd. | Jun 22, 2026 (4d) |
| Jun 16, 2026 | BLTE | ↓ Sell | 10,000 | $140.57 | $1.4M | By Bioptima Ltd. | Jun 17, 2026 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BLTE insiders
Open-market trades in the last 12 months
About Hendrik Peter Scholl's insider trades
Hendrik Peter Scholl is Chief Medical Officer at Belite Bio (BLTE). Since Jun 16, 2026, Hendrik has reported no open-market purchases and 3 sales worth $2.9M on SEC Form 4. In the last 12 months: 3 sales ($2.9M).
Their filings also include other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BLTE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.